Spots Global Cancer Trial Database for myeloma
Every month we try and update this database with for myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | NCT00473590 | Multiple Myelom... | Bevacizumab Bortezomib placebo | 18 Years - | Genentech, Inc. | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Corneal Toxicity in Patients Treated by Belantamab Mafodotin | NCT05887206 | Myeloma Multipl... | Collection of d... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | NCT03850522 | Smoldering Mult... | PD-L1 peptide | 18 Years - | Herlev Hospital | |
| Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma | NCT00794261 | Lymphoma Myeloma | Injection of Pe... Injection of Fi... | 18 Years - | Centre Leon Berard | |
| Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | NCT01315873 | Multiple Myelom... | Bendamustine Bortezomib | 18 Years - | NYU Langone Health | |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment | NCT05063591 | Hematologic Mal... Myelodysplastic... Acute Myeloid L... Lymphoma Leukemia Myeloma | Transfusion sup... | 18 Years - | Brown University | |
| Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | NCT01324947 | Multiple Myelom... | pomalidomide | 18 Years - | Celgene | |
| The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss | NCT03951220 | Myeloma Monoclonal Gamm... Smouldering Mye... | Diffusion Weigh... DXA scan Bloods and urin... | 18 Years - 99 Years | Oxford University Hospitals NHS Trust | |
| Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization | NCT01037517 | Multiple Myelom... Lymphoma | Plerixafor Observation: No... | 18 Years - | CancerCare Manitoba | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | NCT00303719 | Kidney Cancer Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... cyclosporine fludarabine mycophenolate m... stem cell trans... total body irra... filgrastim | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | NCT01695590 | Multiple Myelom... | PRLX 93936 | 18 Years - | Prolexys Pharmaceuticals | |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | NCT00150462 | Waldenstrom's M... Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... | Carfilzomib Dexamethasone | 18 Years - | Amgen | |
| Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma | NCT05353907 | Myeloma | Whole Body MRI | 18 Years - | Guy's and St Thomas' NHS Foundation Trust | |
| Place of the Hevylite Test in the Evaluation of MRD in Myeloma | NCT03702088 | Myeloma | 18 Years - | University Hospital, Montpellier | ||
| Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | NCT01332617 | Myeloma | Simvastatin,Zol... | 18 Years - | University of Louisville | |
| Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | NCT04151667 | Multiple Myelom... | Daratumumab Inj... Dexamethasone O... Lenalidomide Pi... Bortezomib Inje... | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | NCT01177527 | Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L... | 18 Years - | Dana-Farber Cancer Institute | ||
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | NCT04680468 | Myeloma | Belantamab mafo... | 18 Years - | University of Pennsylvania | |
| BAY1238097, First in Man | NCT02369029 | Neoplasms | BAY 1238097 | 18 Years - | Bayer | |
| Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | NCT04155749 | Relapsed and Re... | anitocabtagene-... ARC-T Plus Anti... | 18 Years - | Gilead Sciences | |
| Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | NCT02851056 | Multiple Myelom... | Survivin Vaccin... Autologous Hema... Prevnar 13 Granulocyte-col... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | NCT00968396 | Multiple Myelom... | Apheresis Stem Cell Trans... Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | NCT01042704 | Myeloma | Bendamustine Lenalidomide Dexamethasone Aspirin Prophylaxis Antibiotic Biweekly Follow... Cyclical Follow... Restaging Post-Treatment ... | 18 Years - | University of Pittsburgh | |
| Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology | NCT04703985 | Lymphoma Myeloma | Enteral Nutriti... | 18 Years - | University Hospital, Bordeaux | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Comprehensive Frailty Assessment | NCT02033928 | Myeloma, Multip... Paraproteinemia... Hematologic Neo... | 18 Years - | Ohio State University Comprehensive Cancer Center | ||
| Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | NCT04751877 | Multiple Myelom... Myeloma | Isatuximab Lenalidomide Bortezomib Dexamethasone | 65 Years - 79 Years | Poitiers University Hospital | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma | NCT06212596 | Relapsed or Ref... | Selinexor Cyclophosphamid... Prednisone | 18 Years - | University of Leeds | |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03702725 | Refractory Mult... Multiple Myelom... Multiple Myelom... | Ibrutinib Lenalidomide Dexamethasone | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | NCT00195533 | Hematological M... Leukemia Myelodysplasia Lymphoma Myeloma Stem Cell Trans... | piperacillin-ta... glycopeptide | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Testing a Spanish Version of a Patient Toxicity Questionnaire | NCT01517152 | Breast Cancer Colon Cancer Lung Cancer Lymphoma Myeloma | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | NCT01319422 | Multiple Myelom... | Pomalidomide | 18 Years - | Yale University | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | NCT00361140 | Myelodysplastic... Myeloproliferat... Leukemia, Lymph... Myeloma Lymphoma | Busulfan Fludarabine | 16 Years - 65 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours | NCT00475956 | Neoplasms | AZD2171 AZD0530 | 18 Years - | AstraZeneca | |
| Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | NCT04680468 | Myeloma | Belantamab mafo... | 18 Years - | University of Pennsylvania | |
| BAY1238097, First in Man | NCT02369029 | Neoplasms | BAY 1238097 | 18 Years - | Bayer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | NCT00660166 | Lymphoma Myeloma Leukemia | NK-Cell Infusio... | 13 Years - 70 Years | Tufts Medical Center | |
| Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT | NCT04862676 | Myeloma | Hyperbaric oxyg... | 18 Years - 75 Years | University of Rochester | |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | NCT00597714 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | Non-myeloablati... | 18 Years - | Duke University | |
| African American Cancer Clinical Trial Decisions: Testing Tailored Messages | NCT02356549 | Myeloma Lymphoma Leukemia | EMR Tailoring Survey Tailorin... Physician Invol... | 21 Years - | Virginia Commonwealth University | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients | NCT00111748 | Multiple Myelom... | Velcade, Thalid... | 18 Years - | University of Arkansas | |
| Machine Learning in Myeloma Response | NCT03574454 | Myeloma | Machine Learnin... | 40 Years - 100 Years | Royal Marsden NHS Foundation Trust | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | NCT00382694 | Multiple Myelom... | Fludarabine | 18 Years - 64 Years | Nordic Myeloma Study Group | |
| Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | NCT00532389 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | NCT00580034 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors | Campath Purged ... Donor Apheresis | 17 Years - | Duke University | |
| Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | NCT01319422 | Multiple Myelom... | Pomalidomide | 18 Years - | Yale University | |
| Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | NCT00087867 | Multiple Myelom... | SCIO-469 SCIO-469 and bo... | 18 Years - | Scios, Inc. | |
| MYeloma Resistance And Clonal Evolution | NCT03807128 | Multiple Myelom... | No intervention... | 18 Years - | Nantes University Hospital | |
| Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning | NCT00466674 | Myeloma | reduced intensi... | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | NCT05597345 | Smoldering Mult... | Selinexor | 18 Years - | University of Rochester | |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | NCT00532675 | Multiple Myelom... | LBH589 Lenalidomide | 18 Years - | Novartis | |
| Phase 1 Trial of CXD101 in Patients With Advanced Cancer | NCT01977638 | Advanced Cancer | CXD101 | 18 Years - | Oxford University Hospitals NHS Trust | |
| Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years | NCT01191060 | Myeloma | Lenalidomide, B... Lenalidomide, B... | 18 Years - 65 Years | University Hospital, Toulouse | |
| Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | NCT01861340 | Myeloma | Lenalidomide, D... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma | NCT00120263 | Multiple Myelom... Acute Renal Fai... | Plasma Exchange | 18 Years - 81 Years | London Health Sciences Centre | |
| Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | NCT03500445 | Myeloma Multiple Myelom... | Daratumumab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | NCT02943473 | High Risk Smold... | Ibrutinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | NCT01624701 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Lymphoma Myeloma | Ex vivo expande... | 12 Years - 60 Years | Singapore General Hospital | |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | NCT00606437 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors Hodgkin's Disea... Myelofibrosis | Total Body Irra... | 14 Years - 65 Years | Duke University | |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | NCT00276159 | Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... | 852A | - | Masonic Cancer Center, University of Minnesota | |
| A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | NCT00482261 | Multiple Myelom... | Lenalidomide dexamethasone aspirin | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | NCT01413178 | Myeloma | Busulfan Melphalan Questionnaire G-CSF High Dose Melph... Stem cell trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma | NCT01438177 | Multiple Myelom... | Velcade Cyclophosphamid... Chloroquine | 18 Years - | NYU Langone Health | |
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | NCT03289299 | Smoldering Mult... | Carfilzomib Lenalidomide Daratumumab Dexamethasone | 18 Years - | International Myeloma Foundation | |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy | NCT05154474 | Metastatic Canc... Cancer, Breast Cancer Colon Cancer, Rectum Cancer, Lung Cancer Ovaries Cancer Prostate Cancer, Kidney Cancer Pancreas Myeloma Myelodysplasia Leukemia, Myelo... Leukemia,Myeloi... Leukemia, Lymph... Leukemia, Lymph... | Standard | 18 Years - | Weprom | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
